유방암 액체 생검 시장 규모, 점유율, 동향 분석 보고서 : 순환 바이오마커별, 용도별, 지역별, 부문별 예측(2025-2030년)

Breast Cancer Liquid Biopsy Market Growth & Trends:

The global breast cancer liquid biopsy market size is expected to reach USD 1.90 billion in 2030 and is projected to grow at a CAGR of 8.5% from 2025 to 2030. The growth is attributed to the rising preference for non-invasive methods, rising awareness of early diagnosis and treatment, and rising prevalence of breast cancer. For instance, according to WHO, in 2020, globally, 685,000 women lost their lives to breast cancer, and 2.3 million women were affected by it. Liquid biopsies have been suggested as a revolutionary technique for the early identification of breast cancer, which boosts its adoption and spurs growth.

With the increasing prevalence of breast cancer, there is a high demand to provide proper diagnostics tools for detecting cancer at an early stage and early treatment. There has been increasing R&D in the field of diagnostics to cater to the rising demand. For instance, in June 2022, according to study findings from BioFluidica, patients with HER2-positive breast cancer had success rates while receiving tailored HER2-directed therapy.The clinical significance of liquid biopsy is becoming more well-known as a result of ongoing developments in related fields. Additional interventional clinical trials and the creation of an algorithm to properly combine circulating biomarkers are required to make these technologies widely accessible.

A less intrusive technique for identifying non-hematological malignancies has been developed as a result of technological breakthroughs in continuing research on circulating biomarkers. Compared to traditional tumor biopsy, liquid biopsy is thought to be a promising option for patient monitoring in real time. For instance, in April 2022, Epic Sciences, Inc., launched DefineMBC, a blood test based on liquid biopsy technology for the diagnosis of metastatic breast cancer to its CLIA laboratory portfolio.

Furthermore, key players operating in the market are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in June 2022, NeoGenomics's subsidiary Inivata Limited announced new data for RaDaR assay for the analysis of human epidermal growth factor receptor 2 (HER2)-negative, high-risk patients with minimal residual disease (MRD) and recurrence.

Breast Cancer Liquid Biopsy Market Report Highlights:

• The circulating tumor cells (CTCs) segment is anticipated to grow at the fastest CAGR of 9.4% over the forecast period. There has been ongoing research to specify the utility of CTCs in early-stage breast cancer
• The early detection/screening segment is expected to grow at a significant CAGR of 9.7% during the forecast period, due to the increasing application of the use of liquid biopsy in the early detection of cancer.
• Based on application, the treatment selection segments led the market with the largest revenue share of 51.5% in 2024, attributed to the need to provide early treatment
• North America dominated the breast cancer liquid biopsy market with the largest revenue share of 44.64% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Circulating Biomarkers
  • 1.2.2. Application
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Circulating Biomarkers outlook
  • 2.2.2. Application outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Breast Cancer Liquid Biopsy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Prevalence Of Breast Cancer
    • 3.2.1.2. Increasing Adoption Of Liquid Biopsies In Cancer Diagnosis
    • 3.2.1.3. Need To Provide Early Diagnosis And Treatment
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Cost Associated With Breast Cancer Liquid Biopsy Tests
    • 3.2.2.2. Regulatory & Reimbursement Hurdles
• 3.3. Breast Cancer Liquid Biopsy Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Breast Cancer Liquid Biopsy Market: Circulating Biomarkers Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Breast Cancer Liquid Biopsy Market: Circulating Biomarkers Movement Analysis
• 4.3. Breast Cancer Liquid Biopsy Market by Circulating Biomarkers Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Circulating Tumor Cells (Ctcs)
    • 4.4.1.1. Circulating Tumor Cells (Ctcs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.4.2. Circulating Cell - Free Dna (Cfdna)
    • 4.4.2.1. Circulating Cell - Free Dna (Cfdna) Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.4.3. Extracellular Vesicles (Evs)
    • 4.4.3.1. Extracellular Vesicles (Evs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.4.4. Other Circulating Biomarkers
    • 4.4.4.1. Other Circulating Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Breast Cancer Liquid Biopsy Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Breast Cancer Liquid Biopsy Market: Application Movement Analysis
• 5.3. Breast Cancer Liquid Biopsy Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Early Detection/Screening
    • 5.4.1.1. Early Detection/Screening Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.4.2. Diagnosis
    • 5.4.2.1. Diagnosis Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.4.3. Treatment Selection
    • 5.4.3.1. Treatment Selection Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.4.4. Monitoring
    • 5.4.4.1. Monitoring Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Breast Cancer Liquid Biopsy Market: Regional Estimates & Trend Analysis

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Recent Developments & Impact Analysis by Key Market Participants
• 7.3. Key company market share, 2024
• 7.4. Key Company Profiles
  • 7.4.1. The Menarini Group
    • 7.4.1.1. Company Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. NeoGenomics Laboratories
    • 7.4.2.1. Company Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. F. Hoffmann - La Roche Ltd.,
    • 7.4.3.1. Company Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Myriad Genetics, Inc.
    • 7.4.4.1. Company Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. Thermo Fisher Scientific, Inc.
    • 7.4.5.1. Company Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. QIAGEN
    • 7.4.6.1. Company Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. Biocept, Inc.
    • 7.4.7.1. Company Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. Sysmex Corporation
    • 7.4.8.1. Company Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Strategic Initiatives
  • 7.4.9. Fluxion Biosciences, Inc.
    • 7.4.9.1. Company Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. Epic Sciences, Inc.
    • 7.4.10.1. Company Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Strategic Initiatives